Whereas targeting B-cells may improve renal outcomes following AKI, we showed here that usual serum concentration of ibrutinib cannot prevent the trafficking of B220+ B-cells to the injured kidney following UUO and rhabdomyolysis induced-AKI17. This evidence concerns the gene PTPRC and rhabdomyolysis.